Pieris Pharmaceuticals to Host Key Opinion Leader Event on February 6th

BOSTON, MA--(Marketwired - January 29, 2018) - Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin^® technology platform for cancer, respiratory and other diseases, announced today that it will host a Key Opinion Leader (KOL) Event in New York on Tuesday, February 6^th from 8-10:30 AM EDT.

The KOL event will feature world-class thought leaders in immuno-oncology and respiratory diseases, followed by a company presentation. The event will include presentations from:

• Michael A. Curran, PhD, Assistant Professor in the Department of Immunology and Scientific Director of the Oncology Research for Biologics and Immunotherapy Translation (ORBIT) platform at MD Anderson Cancer Center.
• David H. Ilson, MD PhD, Medical Oncologist and Attending Physician at Memorial Sloan Kettering Cancer Center and Professor at Weill Cornell Medical College.
• Gary Anderson, PhD, FThorSoc, FERS, Professor in the Medical Faculty at the University of Melbourne and Director of the Centre for Lung Health Research.
• Bruce Levy, MD, Parker B. Francis Professor of Medicine at Brigham and Women's Hospital and the Chief of the Pulmonary and Critical Care Division.

The event will be accessible via a live webcast through this link beginning at 8am on February 6^th.

In-person attendance is by invitation only. For more information please contact Clayton Robertson at [email protected].

About Pieris Pharmaceuticals

Pieris is a clinical-stage biotechnology company that discovers and develops Anticalin protein-based drugs to target validated disease pathways in a unique and transformative way. Our pipeline includes immuno-oncology multi-specifics tailored for the tumor microenvironment, an inhaled Anticalin protein to treat uncontrolled asthma and a half-life-optimized Anticalin protein to treat anemia. Proprietary to Pieris, Anticalin proteins are a novel class of therapeutics validated in the clinic and by partnerships with leading pharmaceutical companies. Anticalin^® is a registered trademark of Pieris. For more information, visit www.pieris.com.